Xiaoyan Zhou

3.4k total citations
120 papers, 2.5k citations indexed

About

Xiaoyan Zhou is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Xiaoyan Zhou has authored 120 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 22 papers in Cardiology and Cardiovascular Medicine and 18 papers in Surgery. Recurrent topics in Xiaoyan Zhou's work include Renin-Angiotensin System Studies (14 papers), Blood Pressure and Hypertension Studies (14 papers) and Hormonal Regulation and Hypertension (9 papers). Xiaoyan Zhou is often cited by papers focused on Renin-Angiotensin System Studies (14 papers), Blood Pressure and Hypertension Studies (14 papers) and Hormonal Regulation and Hypertension (9 papers). Xiaoyan Zhou collaborates with scholars based in China, United States and Australia. Xiaoyan Zhou's co-authors include Edward D. Fröhlich, Hidehiko Ono, Dong Ma, Hua Hao, Wei Xue, Dinko Sušić, Luis C. Matavelli, Yuko Ono, Yonghong Huang and Jiake Xu and has published in prestigious journals such as PLoS ONE, Scientific Reports and Cochrane Database of Systematic Reviews.

In The Last Decade

Xiaoyan Zhou

113 papers receiving 2.5k citations

Peers

Countries citing papers authored by Xiaoyan Zhou

Since Specialization

Citations

This map shows the geographic impact of Xiaoyan Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyan Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyan Zhou more than expected).

Fields of papers citing papers by Xiaoyan Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyan Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyan Zhou. The network helps show where Xiaoyan Zhou may publish in the future.

Co-authorship network of co-authors of Xiaoyan Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyan Zhou. A scholar is included among the top collaborators of Xiaoyan Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyan Zhou. Xiaoyan Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efficient antitumor response 2025 ·Communications Biology ·Ping Hou, Li Hu, Junrong Zhang, Xiaoyan Zhou, (unknown), Lijun Li, (unknown), Jing Liu, (unknown), Ling Chen	0
2	Image-based fatigue life prediction of catenary droppers in high-speed railways 2025 ·Engineering Failure Analysis ·Yongming Yao, (unknown), (unknown), Bin Wang, (unknown), Xiaoyan Zhou, (unknown)	0
3	ERK/STAT3 activation through CCL17/CCR4 axis-mediated type 2 cytokine-involved signaling pathways in Th2 cells regulates cutaneous drug reactions 2024 ·International Immunopharmacology ·(unknown), (unknown), Yi Zhang, Xiaoyan Zhou, (unknown), Yi‐Qun Kuang, Yu‐Ye Li	1
4	Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients 2024 ·Translational Lung Cancer Research ·Yuyin Xu, (unknown), Ling Zhang, Haochen Wang, (unknown), Feng Xu, Ran Wei, Qianlan Yao, Min Ren, Tian Xue, Yuan Li, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai	0
5	LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study 2024 ·Annals of Oncology ·(unknown), (unknown), R. Dent, (unknown), (unknown), Sherko Kümmel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jing Zhao, Xiaoyan Zhou, Konstantinos Tryfonidis, Gursel Aktan, (unknown)	5
6	3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2) 2024 ·Heliyon ·Meng‐Yang Xu, Xiaoyue Xiao, (unknown), Xiaoyan Zhou, Luca Parisi, Renfei Ma	3
7	TAT-W61 peptide attenuates neuronal injury through blocking the binding of S100b to the V-domain of Rage during ischemic stroke 2023 ·Journal of Molecular Medicine ·Jia Liang, Hui Li, (unknown), Xiaoyan Zhou, Yanyan Fu, (unknown), Dan Liu, Yuling Chen, (unknown), Zhen Zhang, Xiangru Wen, Guang Zhu, Nan Wang, Yuanjian Song	1
8	Association of Human Leukocyte Antigen Alleles and Hypersensitivity of Efavirenz/Nevirapine in HIV-Infected Chinese Patients 2022 ·AIDS Research and Human Retroviruses ·Xiaoyan Zhou, Chongxi Li, Jianbo Zhang, (unknown), Xi Yang, (unknown), Yu‐Ye Li, Yi‐Qun Kuang	1
9	Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway 2022 ·Experimental Cell Research ·Fen Xu, Jiamin Zhang, Xiaoyan Zhou, Hua Hao	8
10	Association between anthropometric indicators of obesity and cardiovascular risk factors among adults in Shanghai, China 2019 ·BMC Public Health ·Yue Zhang, Yian Gu, Na Wang, Qi Zhao, Nawi Ng, Ruiping Wang, Xiaoyan Zhou, Yonggen Jiang, Weibing Wang, Genming Zhao	28
11	PAN-AMPK Activation Improves Renal Function in a Rat Model of Progressive Diabetic Nephropathy 2019 ·Journal of Pharmacology and Experimental Therapeutics ·Xiaoyan Zhou, Eric S. Muise, (unknown), Iyassu K. Sebhat, Yonghua Zhu, Franklin Liu, Sandra C. Souza, Yanqing Kan, Shirly Pinto, David E. Kelley, Maarten Hoek	19
12	The anti-inflammatory effect of BML-111 on COPD may be mediated by regulating NLRP3 inflammasome activation and ROS production 2018 ·Prostaglandins & Other Lipid Mediators ·Yuan Cao, Xiaoyan Zhou, Zixiao Yin, (unknown), Qingwu Yang, (unknown), (unknown), (unknown), Guogang Xu, (unknown)	31
13	An integrin antagonist (MK‐0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model 2017 ·Pharmacology Research & Perspectives ·Xiaoyan Zhou, (unknown), (unknown), Wei Zhu, Rosemary Mayer‐Ezell, Margarita García‐Calvo, Elizabeth Smith, (unknown), Yanqing Kan, Emanuel Zycband, Yonghua Zhu, Maarten Hoek, Jason M. Cox, Lijun Ma, David E. Kelley, Shirly Pinto	36
14	Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan 2017 ·Journal of Human Hypertension ·(unknown), Jing Li, Xiaoyan Zhou, (unknown), (unknown), Qingtao Meng, Rui Shi, Dai Shi, Xin Chen	5
15	The Impact of Corporate Governance on Chinese Firms Performance: A Board Structure Perspective 2016 ·International Journal of Managerial Studies and Research ·(unknown), Xiaoyan Zhou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
16	Redox poly(ethylene glycol)-b-poly(l-lactide) micelles containing diselenide bonds for effective drug delivery 2015 ·Journal of Materials Science Materials in Medicine ·Xiaolong Zeng, Xiaoyan Zhou, Mengyi Li, Changyong Wang, Jiake Xu, Dong Ma, Wei Xue	32
17	Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension 2011 ·Clinical and Experimental Hypertension ·Xiaoyan Zhou, Martin F. Crook, (unknown), Yonghua Zhu, Zadok Ruben, Yi Pan, (unknown), (unknown), Amy Flattery, Gail Forrest, Daphne Szeto, Huawei Zhao, Sophie Roy, Michael J. Forrest	10
18	Partial Adherence to Antihypertensive Therapy Fails to Achieve Full Cardiovascular Benefits in Hypertensive Rats 2008 ·The American Journal of the Medical Sciences ·Dinko Sušić, Xiaoyan Zhou, Edward D. Fröhlich, Marie Krousel‐Wood	2
19	Lipoxin A4 negatively regulates lipopolysaccharide-induced differentiation of RAW264.7 murine macrophages into dendritic-like cells 2007 ·Chinese Medical Journal ·Li Zhang, Ping Wu, (unknown), Ping Yuan, Jingyuan Wan, Xiaoyan Zhou, Wei Xiong, Feng Fang, Duyun Ye	9
20	Physiologic evidence of renoprotection by antihypertensive therapy 2005 ·Current Opinion in Internal Medicine ·Xiaoyan Zhou, Edward D. Fröhlich	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact